We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM icon
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT icon
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CGEM icon
51
Cullinan Oncology
CGEM
$901M
$4.22M 0.28%
+163,880
New +$5.04M
2021 Q2
0 quarters
DXCM icon
52
DexCom
DXCM
$33.1B
$4.07M 0.27%
38,100
-36,864
-49% -$3.54M
2020 Q4
2 quarters
ELV icon
53
Elevance Health
ELV
$92.9B
$3.87M 0.26%
10,132
-53,760
-84% -$20.5M
2020 Q4
2 quarters
MRK icon
54
CALL
Merck
MRK
$358B
$3.79M 0.25%
+48,700
New +$3.62M
2021 Q2
0 quarters
KDMN
55
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.46M 0.23%
894,995
-478,124
-35% -$1.85M
2020 Q4
2 quarters
EXEL icon
56
Exelixis
EXEL
$15.6B
$3.28M 0.22%
+180,000
New +$4.2M
2021 Q2
0 quarters
AUTL icon
57
Autolus Therapeutics
AUTL
$458M
$3.14M 0.21%
+473,074
New +$2.94M
2021 Q2
0 quarters
MRVI icon
58
Maravai LifeSciences
MRVI
$1.05B
$3.13M 0.21%
+75,000
New +$2.91M
2021 Q2
0 quarters
XENT
59
DELISTED
Intersect ENT, Inc
XENT
$3M 0.2%
175,389
+100,000
+133% +$1.87M
2021 Q1
1 quarter
IPSC icon
60
Century Therapeutics
IPSC
$272M
$2.96M 0.2%
+100,901
New +$2.56M
2021 Q2
0 quarters
LQDA icon
61
Liquidia Corp
LQDA
$3.11B
$2.8M 0.19%
979,049
+479,039
+96% +$1.33M
2021 Q1
1 quarter
TGTX icon
62
TG Therapeutics
TGTX
$8.57B
$2.71M 0.18%
69,760
-692,829
-91% -$27.2M
2018 Q1
13 quarters
ISRG icon
63
Intuitive Surgical
ISRG
$151B
$2.38M 0.16%
7,749
– –
2021 Q1
1 quarter
A icon
64
Agilent Technologies
A
$49.5B
$2.26M 0.15%
15,261
– –
2020 Q4
2 quarters
HSTM icon
65
HealthStream
HSTM
$1.03B
$2.17M 0.14%
+77,812
New +$1.96M
2021 Q2
0 quarters
OCUL icon
66
Ocular Therapeutix
OCUL
$1.62B
$2.13M 0.14%
+150,000
New +$2.28M
2021 Q2
0 quarters
NVAX icon
67
CALL
Novavax
NVAX
$2.11B
$2.12M 0.14%
10,000
– –
2021 Q1
1 quarter
HUMA icon
68
Humacyte
HUMA
$122M
$2.09M 0.14%
205,026
-34,000
-14% -$350K
2021 Q1
1 quarter
ACAD icon
69
CALL
Acadia Pharmaceuticals
ACAD
$3.4B
$2.06M 0.14%
84,600
+59,600
+238% +$1.35M
2021 Q1
1 quarter
TEVA icon
70
CALL
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
$1.91M 0.13%
+192,900
New +$2.04M
2021 Q2
0 quarters
HCA icon
71
HCA Healthcare
HCA
$101B
$1.72M 0.11%
8,314
-77,095
-90% -$15.7M
2020 Q1
5 quarters
MCRB icon
72
Seres Therapeutics
MCRB
$25.4M
$1.42M 0.09%
2,978
-7,786
-72% -$3.29M
2020 Q4
2 quarters
GBT
73
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.4M 0.09%
+40,000
New +$1.56M
2021 Q2
0 quarters
IQV icon
74
IQVIA
IQV
$44.6B
$1.38M 0.09%
5,712
-209
-4% -$48.3K
2020 Q4
2 quarters
TLGT
75
DELISTED
Teligent, Inc
TLGT
$1.34M 0.09%
2,500,260
– –
2021 Q1
1 quarter
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.